AXIM BIOTECHNOLOGIES, INC.

$0.00Close · Oct 7, 2026

News

AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Jan 29, 2026AXIM Biotech
SAN DIEGO, CA – (NewMediaWire) – January 29, 2026 – AXIM Biotechnologies, Inc. (OTC: AXIM) (the “Company”) today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM’s patent for water soluble cannabinoids. At the center of the transactions entered into between the Company and MJNA is AXIM’s U.S. Patent […]
AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids
Jan 29, 2026Press Release | AXIM Biotech
SAN DIEGO, CA – (NewMediaWire) – January 29, 2026 – AXIM Biotechnologies, Inc. (OTC: AXIM) (the “Company”) today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and uses for AXIM’s patent for water soluble cannabinoids. At the center of the transactions entered into between the Company and MJNA is AXIM’s U.S. Patent […]
AXIM Biotechnologies Engages 624 Advisors, owned and managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
Jan 20, 2026AXIM Biotech
San Diego, CA — Jan 20 2026 — AXIM Biotechnologies, Inc. (“AXIM” or the “Company”), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch […]
AXIM Biotechnologies Engages 624 Advisors, owned and managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor
Jan 20, 2026Press Release | AXIM Biotech
San Diego, CA — Jan 20 2026 — AXIM Biotechnologies, Inc. (“AXIM” or the “Company”), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned and managed by Alan J. Touch, OD, as Chief Medical & Regulatory Affairs Advisor. Dr. Touch […]
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement with VisionPlus Corp. for TearScan® Lactoferrin and IgE Diagnostic Tests in South Korea
Oct 23, 2025AXIM Biotech
San Diego, CA — October 23, 2025 — AXIM Biotechnologies, Inc. (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute AXIM’s TearScan® Lactoferrin Test for the detection of aqueous-deficient dry eye (ADDE) and TearScan® IgE Test for ocular allergy throughout South Korea. Under the agreement, VisionPlus receives exclusive […]
AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement with VisionPlus Corp. for TearScan® Lactoferrin and IgE Diagnostic Tests in South Korea
Oct 23, 2025Press Release | AXIM Biotech
San Diego, CA — October 23, 2025 — AXIM Biotechnologies, Inc. (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute AXIM’s TearScan® Lactoferrin Test for the detection of aqueous-deficient dry eye (ADDE) and TearScan® IgE Test for ocular allergy throughout South Korea. Under the agreement, VisionPlus receives exclusive […]
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
Oct 7, 2025AXIM Biotech
Countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, Colombia SAN DIEGO, CA – October 7, 2025 (NEWMEDIAWIRE) – AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostics company focused on rapid, point-of-care ophthalmic testing, today announced it has entered into an exclusive license and distribution agreement with JK Medical, Inc. (“JK Medical”) initially covering seven Latin American countries: […]
AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests
Oct 7, 2025Press Release | AXIM Biotech
Countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, Colombia SAN DIEGO, CA – October 7, 2025 (NEWMEDIAWIRE) – AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostics company focused on rapid, point-of-care ophthalmic testing, today announced it has entered into an exclusive license and distribution agreement with JK Medical, Inc. (“JK Medical”) initially covering seven Latin American countries: […]
Axim Biotechnologies Files Pre-Submission with FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
Jun 24, 2025AXIM Biotech
San Diego, CA – June 24, 2025 – Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration (FDA) as the first formal step in seeking a Clinical Laboratory Improvement Amendments (CLIA) Waiver for […]
Axim Biotechnologies Files Pre-Submission with FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
Jun 24, 2025Press Release | AXIM Biotech
San Diego, CA – June 24, 2025 – Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration (FDA) as the first formal step in seeking a Clinical Laboratory Improvement Amendments (CLIA) Waiver for […]